Dernière modification : 13 nov. 2026, 00:00

Sanofi SA Exchange (PA, EUR)

SAN.PA

87.60
+1.37 (+1.58%)
HealthcareDrug Manufacturers - General
Investir aujourd’hui
Investir aujourd’hui
Rendement sur 1 an (CAGR)
-2.12%
Rendement sur 3 ans (CAGR)
0.61%
Rendement sur 5 ans (CAGR)
0.44%
Rendement sur 10 ans (CAGR)
1.44%
Analyse d’actions

Adobe 3e trimestre 2026 – Le sentiment du marché influence-t-il le prix ?

Lire plus
Capitalisation boursière
105.41B
Cours/chiffre d'affaires
2.10
Valeur d'entreprise
156.49B
Cours/valeur comptable
1.44
Rendement du div
0.00%
Années de croissance
-
Croissance du div
-
Versement FCF
61.54%
Trailing P/E
15.10
PEG
-
P/E prévisionnel
9.46
Croissance EPS
-8.21%

Informations sur les actions

iO Charts Blog

Qu'est-ce qu'une bourse ? Fonctionnement, acteurs, exemples

Lire plus

Graphique boursier

Loading...
Données du prix des actions
Ouverture87.50
Max journalier88.47
Min journalier87.50
Volume journalier2.94M
Niveau record109.62
Estimation des analystes sur 1 an94.10
Beta0.26
EPS (TTM)5.82
Dividende par action0.00
Date ex-div5 May 2026
Prochaine date de bénéfices23 Apr 2026

Prêt à profiter du potentiel de croissance de Sanofi SA ?

Faites le prochain pas dans votre portefeuille.

Investir aujourd’hui

Potentiel de baisse

Loading...
Données du potentiel de baisse
SAN.PAS&P500
Baisse de prix actuelle par rapport au niveau record-20.09%-3.17%
Baisse de prix actuelle la plus importante-55.80%-56.47%
Date de la baisse la plus importante10 Oct 20089 Mar 2009
Baisse moyenne par rapport au record-19.79%-10.64%
Délai moyen pour nouveau record45 days12 days
Délai max pour nouveau record2908 days1805 days
Actualite
MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.
13 novembre 2026
Sanofi (ENXTPA:SAN) expanded its collaboration with Scribe Therapeutics to include access to Scribe's ELXR epigenetic silencing platform. The extended agreement gives Sanofi broader gene editing and e...
13 novembre 2026
The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
13 novembre 2026
Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400 Continued enrollment in first-in-huma...
12 novembre 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
12 novembre 2026
VILNIUS, Lithuania, November 12, 2026--Biomatter, the custom enzyme design company, today announced the closing of an oversubscribed $18 million Series A financing led by Astanor, with participation f...
12 novembre 2026
Recursion Pharmaceuticals Inc (RXRX) showcased durable REC-481 polyp reductions, early REC-1245 activity, over $535 million in partnership inflows and a lowered expense outlook.
11 novembre 2026
We just published a list of the 10 Stocks Analysts Just Upgraded and Sanofi (NASDAQ:SNY) ranked 8th on this list. Wall Street spent last Thursday reminding investors how quickly a favorite theme can t...
10 novembre 2026
Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all. Coverage...
10 novembre 2026
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 3% year on year to $68.3 million. The company’s full-year revenue...
10 novembre 2026